Patents Represented by Attorney Hong Liu
-
Patent number: 8324199Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein the variables A, L1, L2, R2, R11, and M are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.Type: GrantFiled: March 12, 2009Date of Patent: December 4, 2012Assignee: Bristol-Myers Squibb CompanyInventors: James R. Corte, Zilun Hu, Mimi L. Quan
-
Patent number: 8252830Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.Type: GrantFiled: October 8, 2010Date of Patent: August 28, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Donald J. P. Pinto, Joanne M. Smallheer, James R. Corte, Zilun Hu, Cullen L. Cavallaro, Paul J. Gilligan, Mimi L. Quan, Leon M. Smith, II
-
Patent number: 8252795Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.Type: GrantFiled: October 8, 2009Date of Patent: August 28, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Brian E. Fink, Libing Chen, Ashvinikumar V. Gavai, Liqi He, Soong-Hoon Kim, Andrew James Nation, Yufen Zhao, Litai H. Zhang
-
Patent number: 8163749Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, R3 and R11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.Type: GrantFiled: December 13, 2006Date of Patent: April 24, 2012Assignee: Bristol-Myers Squibb CompanyInventor: James R. Corte
-
Patent number: 8101778Abstract: The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.Type: GrantFiled: September 12, 2008Date of Patent: January 24, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Jon J. Hangeland, Mimi L. Quan, Joanne M. Smallheer, Gregory S. Bisacchi, James R. Corte, Todd J. Friends, Zhong Sun, Karen A. Rossi, Cullen L. Cavallaro
-
Patent number: 7955824Abstract: The invention provides novel compounds that may be used as intermediates in the preparation of epothilones, epothilone analogs and derivative, as well as new synthetic methods for producing the intermediates and products.Type: GrantFiled: May 9, 2008Date of Patent: June 7, 2011Assignee: Kosan Biosciences IncorporatedInventors: John R. Carney, Yong Li, Hugo Menzella, Ralph C. Reid
-
Patent number: 7767432Abstract: The present invention relates to improved methods for the production, isolation and purification of epothilone B. These methods include, for example, a fermentation process for the production of epothilone B, isolation via adsorption onto a resin, and subsequent purification.Type: GrantFiled: January 31, 2007Date of Patent: August 3, 2010Assignee: Bristol-Myers Squibb CompanyInventor: Brian L. Davis
-
Patent number: 7754755Abstract: The present invention provides inhibitors of 15-LO according to Formula I, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.Type: GrantFiled: September 21, 2005Date of Patent: July 13, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Natesan Murugesan, John E. Macor, Zhengxiang Gu, Leena Fadnis
-
Patent number: 7723336Abstract: Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are useful as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, Z is N or CR3, and R1, R2, R3, X and Y are as defined herein.Type: GrantFiled: March 21, 2007Date of Patent: May 25, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Wayne Vaccaro, Zhong Chen, Dharmpal S. Dodd, Tram N. Huynh, James Lin, Chunjian Liu, Christopher P. Mussari, John S. Tokarski, David R. Tortolani, Stephen T. Wrobleski, Shuqun Lin
-
Patent number: 7534804Abstract: The present application provides benzoxazole inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.Type: GrantFiled: August 24, 2006Date of Patent: May 19, 2009Assignee: Bristol-Myers Squibb CompanyInventor: David S. Weinstein
-
Patent number: 7470713Abstract: The present invention provides compounds having formula I and their use for the treatment of cancer.Type: GrantFiled: February 18, 2005Date of Patent: December 30, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Anne Marinier, Stephan Roy, Alain Martel
-
Patent number: 7470696Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.Type: GrantFiled: January 23, 2007Date of Patent: December 30, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark D. Wittman
-
Patent number: 7432271Abstract: The present invention provides pyrazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.Type: GrantFiled: September 1, 2004Date of Patent: October 7, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Khehyong Ngu, David S. Weinstein, Jeffrey A. Robl
-
Patent number: 7429611Abstract: The present invention provides indole inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.Type: GrantFiled: September 21, 2005Date of Patent: September 30, 2008Assignee: Bristol-Myers Squibb CompanyInventors: David S. Weinstein, Charles M. Langevine
-
Patent number: 7351727Abstract: The present invention provides oxazolyl and thiazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.Type: GrantFiled: September 1, 2004Date of Patent: April 1, 2008Assignee: Bristol-Myers Squibb CompanyInventor: David S. Weinstein
-
Patent number: RE40387Abstract: The invention relates to methods of increasing the bioavailability of orally administered epothilones. Epothilones administered by the methods of the invention are sufficiently bioavailable to have a pharmacological effect. The invention further relates to pharmaceutical compositions, pharmaceutical dosage forms, and kits for use in the methods of the invention.Type: GrantFiled: June 9, 2005Date of Patent: June 17, 2008Assignee: Bristol-Myers Squibb CompanyInventors: Rebanta Bandyopadhyay, Timothy M. Malloy, Andrea Panaggio, Krishnaswamy Srinivas Raghavan, Sailesh Amilal Varia, Marvin Barry Cohen